Last checked at 27 Jan 2010 15:27
For immediate release: 27 January 2010
KINGSWALK INVESTMENTS LIMITED ("Kingswalk" or the "Company") BOARD CHANGES
Kingswalk Investments Limited (AIM:KWI), the strategic investment company, today announces that Daniel ("Daan") Asse van den Noort, has been appointed to the board of Kingswalk as a Non-executive Director with immediate effect. Daan, 55, is an experienced investment director having previously been a general practitioner until 1996, when he joined the pharmaceutical industry as an executive director of Asta Medical.
From 1999 he joined Ferring Geneesmiddelen as General Manager and in 2001 he joined a venture capital fund, Biotech Turnaround Fund ("BTF") where he is currently Chief Investment Officer, responsible for research and identification of investment opportunities. Through his work at BTF, Daan is currently a director of Genizon Biosciences Inc, Syntarga BV and Metabolex Inc. Daan does not have a shareholding in Kingswalk and there is no further information required to be disclosed under Schedule 2, Paragraph (g) of the AIM Rules for Companies, pursuant to Daan's appointment.
Daan will be replacing Jonathan Freeman on the Company's board as Jonathan has today resigned with immediate effect to concentrate on his other business commitments. The board of Kingswalk would like to wish Jonathan all the very best for the future and to record its thanks for his effort and commitment to the Company over the last five years since its flotation in early 2005.
For further information please contact:
Kingswalk Investments Limited
Paul Everitt
+44 (0)148173 2888
Daniel Stewart & Company Plc
OliverRigby +44(0)20 7776 6550GTH Communications TobyHall +44(0)20 7153 8039ChristianPickel +44 (0)20 7153 8036
vendor